ArticleNeuro-oncology advances
Radiomics based on MRI and
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To develop radiomics methods for predicting response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) based on computed tomography (CT), magnetic resonance imaging (MRI), and positron emission computed tomography (PET) from primary lesion and brain metastasis (BM) in patients with non-small cell lung cancer (NSCLC). Methods: The retrospective study enrolled 140 patients between May 2017 and December 2022 from Center 1, and 45 patients between January 2015 and March 2024 from Center 2. All patients underwent an Results: A total of 7 and 5 important features were selected from primary lesion and BM, respectively. The SUVmax was identified as the most predictive clinical indicator. The developed nomogram based on primary lesion generated AUCs of 0.832, 0.775 and 0.798 in training, internal validation and external validation cohorts, respectively. The nomogram based on BM yielded AUCs of 0.985, 0.921 and 0.956 in training, internal validation and external validation cohorts, respectively. Conclusion: This study indicated that radiomics features from PET/CT and MRI of primary lesion and BM can be predictive of response to EGFR-TKI. The constructed nomogram may be considered as a non-invasive tool to stratify which patient can benefit from the EGFR-TKI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.